Stock listing

NASDAQ:GYRE Gyre Therapeutics, Inc. Stock

Home listing (NASDAQ) of Gyre Therapeutics, Inc.

Follow Gyre Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:GYRE

$4.21 USD -0.13 (-3.0%)

Close on Nov 20, 2026

Past year -43.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.13 – $4.51 USDNov 20, 2026
Volume
240,136 sharesNov 20, 2026
Market cap
$485.5M USDAt the close on Nov 20, 2026 · price × 115.3M shares outstanding
52-week range
$3.97 – $9.14 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.06M USDMedian day 134,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Gyre Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GYRE · Home$4.21 USD-0.13 (-3.0%)240,136$4.40$4.51$4.13$4.34Close on Nov 20, 2026
Frankfurt:L9S€4.08 EUR+0.12 (+3.0%)—€4.08€4.08€4.08€3.96Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GYRE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.21-0.13-3.0%$4.40$4.51$4.13240,136
$4.34-0.22-4.8%$4.52$4.718$4.34466,591
$4.56+0.17+3.9%$4.39$4.60$4.32215,956
$4.39+0.08+1.9%$4.47$4.77$4.35577,140
$4.31+0.01+0.2%$4.65$4.73$4.15278,989
$4.30+0.04+0.9%$4.20$4.36$4.09173,993
$4.26+0.03+0.7%$4.26$4.38$4.22130,505
$4.23-0.42-9.0%$4.63$4.63$4.215141,039
$4.65-0.11-2.3%$4.80$4.80$4.52224,593
$4.76+0.75+18.7%$4.56$4.79$4.08359,700
$4.01-0.43-9.7%$4.50$4.50$3.97266,600
$4.440.000.0%$4.57$4.65$4.33256,500
$4.44-0.29-6.1%$4.61$4.71$4.40239,500
$4.73+0.17+3.7%$4.78$5.11$4.27389,800
$4.56-1.85-28.9%$6.27$6.30$4.52394,100
$6.41-0.68-9.6%$6.86$6.99$6.37185,300
$7.09+0.56+8.6%$6.53$7.10$6.33125,100
$6.53+0.46+7.6%$6.10$6.55$6.01126,400
$6.07+0.22+3.8%$5.77$6.10$5.7793,400
$5.85-0.01-0.2%$5.85$5.90$5.70151,500
$5.86-0.04-0.7%$5.91$6.00$5.8066,600
$5.90-0.27-4.4%$6.21$6.21$5.86131,400
$6.17+0.08+1.3%$6.08$6.34$6.08242,100
$6.09+0.01+0.2%$6.10$6.24$6.05119,200
$6.08-0.32-5.0%$6.41$6.43$6.04142,900
$6.40-0.07-1.1%$6.51$6.65$6.40108,800
$6.47-0.24-3.6%$6.70$6.75$6.44162,800
$6.71-0.16-2.3%$6.89$6.92$6.7185,100
$6.87-0.17-2.4%$7.00$7.07$6.8582,000
$7.04+0.28+4.1%$6.80$7.09$6.7676,600
$6.76-0.28-4.0%$7.04$7.04$6.7482,800
$7.04-0.04-0.6%$7.03$7.15$6.9999,200
$7.08-0.27-3.7%$7.42$7.42$7.01134,000
$7.35+0.24+3.4%$7.17$7.43$7.09181,500
$7.11+0.11+1.6%$7.09$7.35$7.08163,700
$7.00-0.33-4.5%$7.35$7.38$7.00140,000
$7.33+0.01+0.1%$7.32$7.38$7.13159,800
$7.32-0.17-2.3%$7.52$7.74$7.31115,100
$7.49+0.14+1.9%$7.35$7.56$7.30137,000
$7.35+0.02+0.3%$7.39$7.42$7.13134,800
$7.33-0.07-0.9%$7.40$7.44$6.81327,700
$7.40-0.09-1.2%$7.49$7.50$7.04164,500
$7.49+0.06+0.8%$7.40$7.61$7.26227,000
$7.43-0.12-1.6%$7.55$7.57$7.21364,900
$7.55+0.37+5.2%$7.12$7.56$7.101,203,600
$7.18+0.48+7.2%$6.80$7.20$6.80143,200
$6.70+0.01+0.1%$6.70$6.86$6.59126,400
$6.690.000.0%$6.69$6.72$6.4697,800
$6.69-0.04-0.6%$6.82$7.04$6.69104,100
$6.73-0.01-0.1%$6.86$6.95$6.7369,800
$6.74-0.21-3.0%$6.93$6.96$6.7483,100
$6.95-0.22-3.1%$7.17$7.27$6.94104,700
$7.17+0.31+4.5%$6.85$7.20$6.85239,900
$6.86+0.42+6.5%$6.44$6.89$6.4156,000
$6.44+0.08+1.3%$6.37$6.54$6.3641,200
$6.36-0.11-1.7%$6.41$6.67$6.3458,100
$6.47-0.10-1.5%$6.51$6.57$6.3254,500
$6.57-0.02-0.3%$6.60$6.64$6.4341,700
$6.59-0.09-1.3%$6.70$6.70$6.5443,200
$6.68+0.03+0.5%$6.63$6.77$6.6325,300
$6.65-0.03-0.4%$6.71$6.81$6.6038,800
$6.68+0.24+3.7%$6.53$6.72$6.4944,500
$6.44-0.47-6.8%$6.89$6.89$6.4253,300
$6.91-0.11-1.6%$7.08$7.12$6.8666,000
$7.02-0.13-1.8%$7.15$7.29$6.7755,100

Splits

3 splits since 2015 · NASDAQ:GYRE · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
1-for-15Consolidation
1-for-7Consolidation
Ticker
NASDAQ:GYRE
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Gyre Therapeutics, Inc. news

Gyre Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
12 in the last 12 months · 129 in all · newest Nov 5, 2026 · oldest 2019
Decks
10 decks · latest Nov 5, 2026

Where Gyre Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GYRE · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A3EE5FLS ExchangeGermanyEUR
Lang & Schwarz:A3EE5FLang & SchwarzGermanyEUR
BOATS:GYREBOATSUnited StatesUSD
Dusseldorf:L9SDusseldorfGermanyEUR
Frankfurt:L9SFrankfurtGermanyEUR
Stuttgart:L9SStuttgartGermanyEUR
Tradegate:L9STradegateGermanyEUR
gettex:L9SgettexGermanyEUR

Valuation

EV/sales 3.7× against a median of 4.1×: 5th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$428.1M USD
P/E
Loss
EV/sales
3.7×
EV/EBITDA
Negative EBITDA
Price/book
4.5×
Gross margin
93.9%
Operating margin
−13.1%
Net margin
−25.8%
Debt to equity
0.0×
Beta vs S&P 500
1.44

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Gyre Therapeutics, Inc. · NASDAQ:GYREUS$485.5MUS$428.1Mn/a3.7×n/a4.5×−25.8%0.0×1.44
Egetis Therapeutics AB · OMXSTO:EGTXUS$505.7MUS$475.4Mn/a73.5×n/a10.7×−613.5%0.1×n/a
Hunan Hansen Pharmaceutical Co., Ltd. Class A · SZSE:002412US$497.4MUS$420.9M12.2×2.8×n/a1.4×27.0%0.0×n/a
Gujarat Themis Biosyn Ltd · NSE:GUJTHEMUS$495.4MUS$512.4M94.3×27.3×57.6×15.9×28.0%0.6×n/a
Valneva SE · EURONEXT:VLAUS$491.8MUS$589.2Mn/a3.8×n/a5.5×−110.3%2.6×n/a
Xizang Weixinkang Pharmaceutical Co., Ltd. Class A · SSE:603676US$483.6MUS$331.9M17.0×2.0×n/a2.0×17.4%0.0×n/a
Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A · SSE:603207US$480.5MUS$372.4M16.6×4.5×n/a2.8×34.9%0.0×n/a
SMS Pharmaceuticals Limited · NSE:SMSPHARMAUS$478.3MUS$478.3M43.3×4.9×22.7×5.6×11.4%0.0×n/a
Aarti Drugs Limited · NSE:AARTIDRUGSUS$477.2MUS$543.0M19.3×1.8×13.1×2.6×8.0%0.4×n/a
Sinotherapeutics, Inc. Class A · SSE:688247US$471.2MUS$349.3M174×5.9×n/a2.4×4.5%0.0×n/a
Ocumension Therapeutics · HKEX:1477US$464.3MUS$429.0Mn/a3.6×n/a0.9×−19.8%0.1×n/a
Median of the othersUS$482.0MUS$452.2M19.3×4.1×22.7×2.7×9.7%0.0×

Forecasts

3 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
18.67 USD · Analysts' mean
EPS, year to Dec 2026
-0.28 · 2 analysts
Revenue, year to Dec 2026
112.6M · 3 analysts

Team and board

Officers

OfficerRole
Ying LuoChief Executive Officer
Thomas EastlingChief Financial Officer
Weiguo YeChief Operating Officer
Joshua BergmannGeneral Counsel and Corporate Secretary
Jialiang WangExecutive Vice President, General Manager
Jing LiuSenior Vice President - Platform Chemistry
Leslie RobinsonVice President - Intellectual Property and Licensing
Liang ZhaoVP Corporate Controller
Mark MarinoSenior Vice President-Clinical Development
Michael PleweSenior Vice President - Medicinal Chemistry
Seth GoldblumSenior Vice President - Corporate Development
David ZhangChief Business
Ruoyu ChenChief Information Officer
Yue XiongChief Scientific Officer

Board

DirectorRole
Ping ZhangChairman
Claire WestonBoard Member
Dan WengBoard Member
Gordon G. CarmichaelBoard Member
Maxwell KirkbyBoard Member
Renate ParryBoard Member
Rodney L. NussbaumBoard Member
Ying LuoChief Executive Officer
Yue XiongChief Scientific Officer

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+18.7%
Q2 2026Aug 7, 2026+5.0%
Q1 2026May 7, 2026 · Before open−12.1%
Q4 2025Mar 31, 2026+5.7%
Q3 2025Nov 7, 2025 · Before open−1.8%
Q2 2025Aug 11, 2025 · After close+6.9%
Q1 2025May 9, 2025 · Before open+0.5%
Q4 2024Mar 24, 2025 · Before open−5.2%
Q3 2024Nov 4, 2024 · After close+1.6%
Q2 2024Aug 12, 2024 · Before open+2.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−2.7%
Q4 2023Mar 27, 2024+4.1%
Q3 2023Oct 26, 2023 · After close−1.9%
Q2 2023Aug 3, 2023−5.7%
Q1 2023May 4, 20230.0%
Q4 2022Mar 9, 2023−13.0%
Q3 2022Nov 23, 20220.0%
Q2 2022Aug 15, 2022−1.6%
Q1 2022May 9, 2022−24.5%
Q4 2021Mar 31, 20220.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck25 slidesNov 5, 2026
Investor Presentation (September 2026)Investor deck26 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck44 slidesAug 26, 2026
Investor Presentation (June 2026)Investor deck42 slidesJun 2, 2026
Investor Presentation (May 2026)Investor deck21 slidesMay 14, 2026
Merger or Acquisition (March 2026)Merger or acquisition39 slidesMar 2, 2026
H.C. Wainwright Global Investment Conference 2025Conference18 slidesSep 10, 2025
Technical Presentation (May 2025)Technical28 slidesMay 22, 2025
Investor Presentation (April 2025)Investor deck24 slidesApr 28, 2025
Technical Presentation (September 2021)Technical14 slidesSep 9, 2021

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$23M raised · US$9 a share · Jefferies +1
Dealers: Jefferies (lead), H.C. Wainwright & Co.
Use of proceeds: Advance Phase 2 trial of F351 in MASH-associated liver fibrosis in the US, R&D, manufacturing and scale-up, working capital and general corporate purposes
May 29, 2025
Public offering of common stock
Announced: Jefferies +1
Dealers: Jefferies (lead), H.C. Wainwright & Co.
Use of proceeds: Advance Phase 2 trial of F351 in MASH-associated liver fibrosis in the US, R&D, manufacturing and scale-up, working capital and general corporate purposes
May 22, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue116.6M105.8M113.5M102.3M7.34M20.9M6.00K1.02M
Cost of revenue5.42M3.88M4.64M4.79M
Gross profit111.2M101.9M108.8M97.5M
Research and development13.7M12.0M13.8M16.7M68.9M53.0M43.9M21.5M12.8M11.6M
Operating income11.5M16.2M-67.2M9.20M-87.9M-57.4M-57.3M-33.8M-21.8M-20.4M
Depreciation and amortization2.48M1.55M1.07M1.09M290.0K138.0K146.0K149.0K173.0K389.0K
EBITDA14.0M17.7M-66.2M10.3M-87.6M-57.2M-57.1M-33.7M-21.6M-20.0M
Income before tax14.4M23.2M-77.0M9.41M-87.9M
Income tax4.56M5.32M8.52M5.10M
Net income9.88M17.9M-85.5M4.31M-87.9M-56.2M-55.2M-30.1M-21.6M-16.9M
Earnings per share, basic0.060.14-1.410.04-2.87-2.93-4.60-2.68-7.45-21.75
Earnings per share, diluted0.020.05-1.410.03-2.87-2.93-4.60-2.68-7.45-21.75

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents49.2M11.8M33.5M25.2M44.3M30.4M15.4M31.2M14.5M10.3M
Short-term investments15.4M14.9M02.50M49.0M61.5M88.9M18.0M6.80M
Receivables31.1M19.6M15.2M1.82M3.31M15.0M
Inventory10.2M6.34M4.28M6.12M
Current assets149.4M64.8M57.2M49.7M51.5M89.5M96.1M124.0M39.1M37.5M
Property, plant and equipment27.5M23.9M23.3M17.7M970.0K433.0K304.0K386.0K276.0K444.0K
Total assets219.8M125.4M116.5M84.8M55.7M94.8M98.6M124.9M39.5M38.1M
Accounts payable1.33M108.0K355.0K122.0K6.42M5.93M4.28M1.25M747.0K837.0K
Current liabilities23.8M19.5M20.0M12.2M14.2M17.8M28.9M4.80M8.74M22.0M
Total liabilities31.4M27.0M38.1M12.5M14.6M18.8M30.2M4.97M8.74M22.0M
Shareholders' equity62.5M63.3M-15.8M42.5M41.1M76.1M68.3M119.9M30.8M16.1M
Shares outstanding91.3M86.3M76.6M63.6M31.4M22.1M12.0M12.0M6.08M801.8K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations1.01M-3.64M25.9M10.7M-83.8M-55.0M-43.6M-28.6M-19.9M-18.5M
Capital spending-1.19M-2.31M-8.52M-4.99M-839.0K-64.0K-376.0K-23.0K-468.0K
Free cash flow-180.0K-5.96M17.4M5.69M-84.6M-43.7M-28.9M-20.0M-18.9M
Cash from investing-474.0K-19.9M-19.8M-13.8M48.2M9.66M27.4M-71.3M-11.2M-1.31M
Cash from financing24.4M2.10M2.50M-45.0M49.6M60.4M327.0K111.3M21.1M948.0K
Dividends paid-45.0M
Change in cash25.3M-21.7M8.33M-5.03M14.0M15.0M-15.9M11.5M-10.1M-18.8M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
8-K · Current reportOct 22, 2026Management or board changeSEC
8-K · Current reportSep 1, 2026Current reportSEC
S-8 · Registration statement for employee plansAug 28, 2026Offer documentSEC
8-K · Current reportAug 26, 2026Current reportSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
8-K · Current reportAug 7, 2026ResultsSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipAug 4, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 4, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 4, 2026Other filingsSEC
8-K · Current reportJul 16, 2026Management or board changeSEC
8-K/A · Current report, amendedJul 15, 2026ResultsSEC
S-3/A · Registration statement, amendedJul 13, 2026Offer documentSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
S-3 · Registration statementJun 22, 2026Offer documentSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 16, 2026Meeting outcomeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 9, 2026Offer documentSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
8-K · Current reportJun 2, 2026Current reportSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
8-K · Current reportMay 14, 2026Current reportSEC
8-K · Current reportMay 12, 2026Current reportSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 7, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 7, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
8-K · Current reportMay 6, 2026ResultsSEC
DEFA14A · Additional proxy materialMay 4, 2026Meeting noticeSEC
8-K · Current reportMay 4, 2026Acquisition or disposalSEC
ARS · Annual report to shareholdersApr 27, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
8-K/A · Current report, amendedApr 17, 2026Material contractSEC
PRE 14A · Preliminary proxy statementApr 16, 2026Meeting noticeSEC
8-K · Current reportMar 23, 2026Current reportSEC
10-K · Annual reportMar 13, 2026Annual reportSEC
8-K · Current reportMar 12, 2026Current reportSEC
8-K · Current reportMar 11, 2026ResultsSEC
8-K · Current reportMar 2, 2026Material contractSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
8-K · Current reportJan 5, 2026Current reportSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportSep 10, 2025Current reportSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 26, 2025Insider tradeSEC
8-K · Current reportAug 22, 2025Management or board changeSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
8-K · Current reportJun 5, 2025Meeting outcomeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
4 · Change in ownershipMay 27, 2025Insider tradeSEC
8-K · Current reportMay 23, 2025Material contractSEC
424B5 · ProspectusMay 23, 2025Offer documentSEC
424B5 · ProspectusMay 22, 2025Offer documentSEC
8-K · Current reportMay 22, 2025Current reportSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
8-K · Current reportApr 28, 2025Current reportSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 22, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 21, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2025Meeting noticeSEC
4 · Change in ownershipApr 18, 2025Insider tradeSEC
4 · Change in ownershipMar 25, 2025Insider tradeSEC
4 · Change in ownershipMar 21, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 20, 2025Offer documentSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
10-K · Annual reportMar 17, 2025Annual reportSEC
8-K · Current reportMar 17, 2025ResultsSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
8-K · Current reportFeb 18, 2025ResultsSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 29, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 21, 2025Insider tradeSEC
4 · Change in ownershipJan 16, 2025Insider tradeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4/A · Change in ownership, amendedJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
8-K · Current reportJan 6, 2025Management or board changeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 19, 2024Insider tradeSEC
8-K · Current reportNov 27, 2024Material contractSEC
424B5 · ProspectusNov 27, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 25, 2024Other filingsSEC
CORRESP · Letter to the SECNov 20, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 20, 2024Other filingsSEC
S-3 · Registration statementNov 14, 2024Offer documentSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13D · Big-stake noticeSep 6, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeSep 6, 2024Big-stake noticeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 8, 2024Insider tradeSEC
8-K · Current reportAug 8, 2024Management or board changeSEC
144 · Notice of proposed saleJul 18, 2024Other filingsSEC
144 · Notice of proposed saleJul 17, 2024Other filingsSEC
144 · Notice of proposed saleJul 16, 2024Other filingsSEC
144 · Notice of proposed saleJul 15, 2024Other filingsSEC
RW · Request to withdraw a registrationJul 12, 2024Other filingsSEC
RW · Request to withdraw a registrationJul 12, 2024Other filingsSEC
8-K · Current reportJul 5, 2024Management or board changeSEC
144 · Notice of proposed saleJul 3, 2024Other filingsSEC
144 · Notice of proposed saleJul 2, 2024Other filingsSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
144 · Notice of proposed saleJul 1, 2024Other filingsSEC
144 · Notice of proposed saleJun 28, 2024Other filingsSEC
8-K · Current reportJun 17, 2024Meeting outcomeSEC
S-3 · Registration statementMay 30, 2024Offer documentSEC
8-K · Current reportMay 30, 2024Current reportSEC
S-3 · Registration statementMay 30, 2024Offer documentSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
8-K · Current reportMay 8, 2024Current reportSEC
4 · Change in ownershipMay 2, 2024Insider tradeSEC
144 · Notice of proposed saleMay 1, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 19, 2024Meeting noticeSEC
144 · Notice of proposed saleApr 9, 2024Other filingsSEC
144 · Notice of proposed saleApr 8, 2024Other filingsSEC
144 · Notice of proposed saleApr 5, 2024Other filingsSEC
144 · Notice of proposed saleApr 4, 2024Other filingsSEC
144 · Notice of proposed saleApr 3, 2024Other filingsSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
144 · Notice of proposed saleApr 2, 2024Other filingsSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Gyre Therapeutics, Inc.’s releases · as of Nov 1, 2026

Common shares
115,321,017
Fully diluted
115,321,017

Fully diluted

LineSharesAs of
Common shares115,321,017Nov 1, 2026

Share count over time

CountShares
Nov 1, 2026115,321,017

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
HSG Holding Ltd3.75M3.3%US$27.5MSep 30, 2026
Vanguard1.83M1.6%US$13.4MSep 30, 2026
BlackRock1.18M1.0%US$8.61MSep 30, 2026
Octagon Capital Advisors LP954K0.83%US$7MSep 30, 2026
Geode Capital681K0.59%US$5MSep 30, 2026
Schwab263K0.23%US$1.93MSep 30, 2026
State Street247K0.21%US$1.81MSep 30, 2026
UBS211K0.18%US$1.55MSep 30, 2026
Northern Trust190K0.16%US$1.39MSep 30, 2026
SBI Securities Co., Ltd.170K0.15%US$1.24MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
AllianceBernstein67,7900.06%US$497KSep 30, 2026
Goldman Sachs59,9820.05%US$440KSep 30, 2026
BNY56,2410.05%US$412KSep 30, 2026
Strs Ohio40,4000.04%US$296KSep 30, 2026
Barclays32,9750.03%US$242KSep 30, 2026
Nuveen30,0040.03%US$220KSep 30, 2026
Morgan Stanley29,2520.03%US$214KSep 30, 2026
Bank of America28,4470.02%US$209KSep 30, 2026
Dimensional25,2680.02%US$185KSep 30, 2026
Millennium20,1360.02%US$148KSep 30, 2026
Rhumbline Advisers18,6050.02%US$136KSep 30, 2026
DWS15,6900.01%US$115KSep 30, 2026
T. Rowe Price15,0310.01%US$111KSep 30, 2026
Fidelity11,8490.01%US$86,853Sep 30, 2026
Brevan Howard Capital Management LP10,977<0.01%US$80,461Sep 30, 2026
JPMorgan7,728<0.01%US$56,568Sep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.7,505<0.01%US$55,012Sep 30, 2026
Wells Fargo4,218<0.01%US$30,918Sep 30, 2026
BNP Paribas3,948<0.01%US$28,939Sep 30, 2026
Russell Investments Group, Ltd.3,848<0.01%US$28,205Sep 30, 2026
Tower Research Capital LLC (TRC)3,073<0.01%US$22,525Sep 30, 2026
New York State Common Retirement Fund2,700<0.01%US$19,791Sep 30, 2026
Police & Firemen's Retirement System of New Jersey2,392<0.01%US$17,533Sep 30, 2026
Federated Hermes, Inc.1,648<0.01%US$12,080Sep 30, 2026
Legal & General1,383<0.01%US$10,137Sep 30, 2026
RBC825<0.01%US$6,000Sep 30, 2026
Citigroup Inc774<0.01%US$5,673Sep 30, 2026
Ameritas Investment Partners, Inc.683<0.01%US$5,006Sep 30, 2026
Activest Wealth Management533<0.01%US$3,907Sep 30, 2026
Sterling Capital Management LLC508<0.01%US$3,724Sep 30, 2026
Strategic Financial Concepts, LLC461<0.01%US$3,379Sep 30, 2026
Global Retirement Partners, LLC435<0.01%US$3,189Sep 30, 2026
Farther Finance Advisors, LLC361<0.01%US$2,646Sep 30, 2026
California State Teachers Retirement System166<0.01%US$1,217Sep 30, 2026
Arax Advisory Partners86<0.01%US$630Sep 30, 2026
Allworth Financial LP57<0.01%US$418Sep 30, 2026
GoalVest Advisory LLC50<0.01%US$367Sep 30, 2026
Osaic Holdings, Inc.38<0.01%US$278Sep 30, 2026
Covestor Ltd29<0.01%Sep 30, 2026
EverSource Wealth Advisors, LLC16<0.01%US$117Sep 30, 2026

This page holds 50 of 54 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund615K0.53%US$4.05MJun 30, 2026
iShares Russell 2000 ETF394K0.34%US$2.6MJun 30, 2026
Vanguard Extended Market Index Fund239K0.21%US$1.57MJun 30, 2026
Fidelity Small Cap Index Fund200K0.17%US$1.15MJul 31, 2026
iShares Russell 2000 Growth ETF121K0.10%US$796KJun 30, 2026
Fidelity Extended Market Index Fund111K0.10%US$657KMay 31, 2026
Schwab U.S. Small-Cap ETF99,8920.09%US$590KMay 31, 2026
Fidelity Nasdaq Composite Index Fund60,2380.05%US$356KMay 31, 2026
Vanguard Russell 2000 Index Fund60,0980.05%US$355KMay 31, 2026
Schwab Small-Cap Index Fund44,8770.04%US$258KJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Russell 2000 Value ETF41,6530.04%US$274KJun 30, 2026
Master Small Cap Index Series41,6160.04%US$274KJun 30, 2026
Fidelity Total Market Index Fund37,5090.03%US$222KMay 31, 2026
Fidelity Series Total Market Index Fund31,9530.03%US$189KMay 31, 2026
Nuveen Small Cap Blend Index Fund24,5050.02%US$141KJul 31, 2026
Goldman Sachs Absolute Return Tracker Fund22,7330.02%US$150KJun 30, 2026
Schwab Total Stock Market Index Fund20,9840.02%US$121KJul 31, 2026
WisdomTree U.S. SmallCap Fund19,7180.02%US$130KJun 30, 2026
Schwab U.S. Broad Market ETF18,0000.02%US$106KMay 31, 2026
EQ/2000 Managed Volatility Portfolio17,7490.02%US$117KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund12,6760.01%US$83,535Jun 30, 2026
Fidelity Small Cap Growth Index Fund11,9030.01%US$78,441Jun 30, 2026
EQ/Small Company Index Portfolio11,180<0.01%US$73,676Jun 30, 2026
Vanguard Russell 2000 Growth Index Fund11,044<0.01%US$65,270May 31, 2026
Vanguard Balanced Index Fund10,904<0.01%US$71,857Jun 30, 2026
U.S. Micro Cap Portfolio9,892<0.01%US$56,879Jul 31, 2026
U.S. Small Cap Portfolio9,831<0.01%US$56,528Jul 31, 2026
Small Cap Index Fund8,984<0.01%US$59,205Jun 30, 2026
Global X Russell 2000 ETF8,775<0.01%US$50,456Jul 31, 2026
ATM Small Cap Managed Volatility Portfolio8,768<0.01%US$57,781Jun 30, 2026
EQ/AB Small Cap Growth Portfolio8,460<0.01%US$55,751Jun 30, 2026
Fidelity Small Cap Value Index Fund7,911<0.01%US$52,133Jun 30, 2026
Small Cap Core Fund6,593<0.01%US$43,448Jun 30, 2026
LVIP State Street Small-Cap Index Fund5,500<0.01%US$36,245Jun 30, 2026
Small Cap Index Fund5,447<0.01%US$32,192May 31, 2026
Small-Cap Index Portfolio4,945<0.01%US$32,588Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio4,800<0.01%US$31,632Jun 30, 2026
NVIT Small Cap Index Fund4,161<0.01%US$27,421Jun 30, 2026
GuideMark Small/Mid Cap Core Fund3,537<0.01%US$23,309Jun 30, 2026
BlackRock Small Cap Index V.I. Fund2,952<0.01%US$19,454Jun 30, 2026
DWS Small Cap Index VIP2,866<0.01%US$18,887Jun 30, 2026
T. Rowe Price Small-Cap Index Fund2,764<0.01%US$18,215Jun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund2,488<0.01%US$16,396Jun 30, 2026
Nationwide Fundamental All Cap Equity Portfolio2,423<0.01%US$13,932Jul 31, 2026
SA Small Cap Index Portfolio2,254<0.01%US$12,961Jul 31, 2026
Nationwide Small Cap Index Fund2,053<0.01%US$11,805Jul 31, 2026
Siit Extended Market Index Fund2,000<0.01%US$11,820May 31, 2026
Avantis U.S. Small Cap Equity ETF1,907<0.01%US$11,270May 31, 2026
iShares Russell Small/Mid-Cap Index Fund1,694<0.01%US$9,741Jul 31, 2026
Total Stock Market Index Trust1,460<0.01%US$9,621Jun 30, 2026

This page holds 50 of 77 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Ye Weiguo
Officer: Chief Operating Officer
Sale3,000USD 6.35US$19,050Jun 18, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale2,800USD 6.17US$17,276Jun 11, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale5,000USD 6.24US$31,200Jun 10, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale6,418USD 6.21US$39,856Jun 10, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale3,000USD 6.15US$18,450Jun 9, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale14,500USD 6.14US$89,030Jun 9, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale15,401USD 6.40US$98,566Jun 5, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale19,575USD 6.13US$120KJun 4, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale4,000USD 6.10US$24,400May 26, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale3,500USD 6.08US$21,280May 22, 2026
All 18 trades
TradeTradeSharesPriceValueDate
Ye Weiguo
Officer: Chief Operating Officer
Sale12,820USD 6.15US$78,843May 21, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale9,400USD 6.15US$57,810May 20, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale9,120USD 6.37US$58,094May 19, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale200USD 6.62US$1,324May 18, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale13,100USD 6.65US$87,115May 15, 2026
Ye Weiguo
Officer: Chief Operating Officer
Sale15,580USD 6.91US$108KMay 14, 2026
Luo Ying
Director, Officer: Chief Executive Officer
Sale10,136USD 8.04US$81,493May 6, 2026
Luo Ying
Director, Officer: Chief Executive Officer
Sale179USD 8.01US$1,434May 5, 2026

Big stakes

StakeStakeSharesDateFiling
GNI Group Ltd.69.10%86.3MMay 4, 2026Schedule 13D
Ying Luo8.60%10.2MMay 4, 2026Schedule 13D
Songjiang Ma6.33%7.34MMay 4, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alan W. Dunton
Other companies: CorMedix Inc. (Director · Since at least Mar 1, 2019); Palatin Technologies, Inc. (Director · Since at least Jun 22, 2011); Oragenics Inc. (Director · Since at least Apr 1, 2011); Adams Respiratory Therapeutics Inc (Director · Nov 8, 2006 – Jan 29, 2008 · Past); MediciNova, Inc. (Director · May 11, 2006 – Jun 11, 2010 · Past)
Director · Oct 18, 2006 – Aug 14, 2015 · Past
Augustine Lawlor
Other companies: PRF Technologies Ltd. (Director · Since at least Mar 18, 2026); Cypherpunk Technologies Inc. (Chief Operating Officer · Since at least Jan 20, 2017); Globeimmune Inc (Director · Jul 1, 2014 – Mar 18, 2016 · Past); Cardiovascular Systems Inc (Director · Aug 31, 2012 – Apr 27, 2023 · Past); Human Genome Sciences Inc (Director · Oct 10, 2011 – Jul 30, 2012 · Past)
Director · Aug 20, 2015 – Aug 31, 2023 · Past
Jeff Himawan
Other companies: Horizon Pharma PLC (Director · Jul 28, 2011 – May 3, 2018 · Past); Iomai Corp (Director · Jan 25, 2006 – Oct 25, 2006 · Past); MediciNova, Inc. (Director · Jan 9, 2006 – Jun 14, 2011 · Past)
Director · Aug 20, 2015 – Aug 20, 2015 · Past
Steven Burrill
Other companies: ADMA Biologics Inc (Director · Feb 13, 2012 – Feb 13, 2012 · Past); Clinical Data Inc (Director · Dec 23, 2005 – Dec 23, 2005 · Past); Depomed Inc (Director · Dec 8, 2005 – Dec 10, 2013 · Past)
Director · Aug 16, 2006 – Jul 31, 2012 · Past
Charles A Blixt
Other companies: Lamb Weston Holdings, Inc. (Director · Nov 8, 2016 – Dec 23, 2024 · Past); Krispy Kreme Doughnuts Inc (Director · Sep 12, 2006 – Jul 27, 2016 · Past)
Director · Apr 11, 2006 – Aug 14, 2015 · Past
Eddie Williams
Other companies: BioAtla, Inc. (Director · Since at least Dec 16, 2021); BiomX Inc. (Director · Oct 12, 2023 – Apr 14, 2025 · Past)
Director · Jan 2, 2018 – Jan 7, 2022 · Past
David M Epstein
Other companies: Black Diamond Therapeutics, Inc. (SEE REMARKS, Director · Jan 29, 2020 – Jun 27, 2023 · Past)
Director · Since at least Aug 6, 2024
Geoffrey M D Ling
Other companies: Celularity Inc. (Director · Since at least Aug 31, 2023)
Director · Jan 15, 2020 – Jan 7, 2022 · Past
John P Richard
Other companies: Vaxart, Inc. (Director · Aug 13, 2013 – Oct 11, 2019 · Past)
Director · Apr 11, 2006 – Mar 13, 2020 · Past
Julia R Brown
Other companies: Albireo Pharma Inc (Director · Apr 24, 2012 – Jun 7, 2018 · Past)
Director · May 12, 2010 – Aug 14, 2015 · Past
All 44 people
PersonSeat
Peter A Zorn
Other companies: Albireo Pharma Inc (Chief Corp. Officer, GC & Sec · Nov 3, 2016 – Aug 21, 2017 · Past)
SVP, Lgl Affrs, GC & Secretary · Dec 19, 2007 – Jan 17, 2013 · Past
Veronica Cai
Other companies: Valion Bio, Inc. (Chief Financial Officer · Apr 1, 2022 – Apr 1, 2022 · Past)
Controller · Aug 30, 2019 – Mar 13, 2020 · Past
Charles C WuChief Executive Officer, Director · Oct 30, 2023 – Nov 20, 2023 · Past
Claire WestonBoard Member · Since at least Jul 16, 2026
Dan WengBoard Member · Since at least Aug 18, 2025
David A HosfordVP, Clin Dev & Reg Affairs · Jan 23, 2014 – Jan 23, 2014 · Past
David ZhangChief Business · Since at least Jan 5, 2026
Edwin MadisonChief Scientific Officer · Aug 20, 2015 – Oct 22, 2015 · Past
Gordon G. CarmichaelBoard Member · Since at least Oct 30, 2023
Grant E BlouseChief Scientific Officer · Jul 12, 2021 – Aug 9, 2022 · Past
Han YingChief Executive Officer, Director · Oct 30, 2023 – Aug 14, 2024 · Past
Howard LevyChief Medical Officer · Apr 18, 2016 – Aug 9, 2021 · Past
Jialiang WangExecutive Vice President, General Manager · Since at least Nov 5, 2026
Jing LiuSenior Vice President - Platform Chemistry · Since at least Nov 5, 2026
Joshua BergmannGeneral Counsel and Corporate Secretary · Since at least Nov 5, 2026
Leslie RobinsonVice President - Intellectual Property and Licensing · Since at least Nov 5, 2026
Liang ZhaoVP Corporate Controller · Since at least Nov 5, 2026
Mark MarinoSenior Vice President-Clinical Development · Since at least Nov 5, 2026
Mauri K HodgesTreasurer, CFO · May 4, 2012 – Aug 14, 2015 · Past
Maxwell KirkbyBoard Member · Since at least Jul 16, 2026
Merouane BencherifSVP and Senior Scien Fellow · Apr 11, 2006 – Jan 17, 2013 · Past
Michael PleweSenior Vice President - Medicinal Chemistry · Since at least Nov 5, 2026
Nassim UsmanDirector · Feb 8, 2021 – Jun 28, 2024 · Past
Patrick C RockSecretary, GC · Aug 14, 2015 – Aug 14, 2015 · Past
Ping ZhangChairman · Since at least Jan 5, 2025
Renate ParryDirector · Since at least Oct 30, 2023
Rodney L. NussbaumBoard Member · Since at least Mar 20, 2024
Ruoyu ChenChief Information Officer · Since at least Oct 30, 2023
Seth GoldblumSenior Vice President - Corporate Development · Since at least Nov 5, 2026
Thomas EastlingChief Financial Officer · Since at least Dec 26, 2022
Weiguo YeChief Operating Officer · Since at least Oct 30, 2023
William S CaldwellSVP - Drug Discovery and Dev. · Jan 9, 2009 – Sep 20, 2011 · Past
Ying LuoChief Executive Officer, Director · Since at least Dec 26, 2022
Yue XiongChief Scientific Officer · Since at least May 4, 2026

Open People

Log in to ask 6ix AI your own questions about Gyre Therapeutics, Inc.